Harbour BioMed’s WIN378 Shows Positive Phase 2 Asthma Data
Cambridge, Massachusetts, U.S.; Rotterdam, Netherlands; and Shanghai, China, September 8, 2026 Harbour BioMed has announced positive interim results from...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Cambridge, Massachusetts, U.S.; Rotterdam, Netherlands; and Shanghai, China, September 8, 2026 Harbour BioMed has announced positive interim results from...
Shanghai, China, September 8, 2026 Alebund Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has cleared...
